Please assess the completion status of the following clinical trial:

Trial Title: Outcomes With Immune Checkpoint Inhibitor for Patients With Non-Small-Cell Lung Cancer and Stable Brain Metastases

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 1.Diagnosed with advanced non-small cell lung cancer 2.Patients with brain metastasis 3. Treated with ICIs~Exclusion Criteria:~* 1.Patients with a clear driver mutation that can be targeted for first-line treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chemotherapy alone or chemotherapy combined with anti-angiogenesis (Type: None): patients with Chemotherapy
- immuntherapy (Type: None): patients treated with immune checkpoint inhibitor monotherapy or combination therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).